395 related articles for article (PubMed ID: 24692678)
1. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib for ovarian cancer.
Leone Roberti Maggiore U; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Investig Drugs; 2013 Aug; 22(8):1049-62. PubMed ID: 23675696
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in patients with refractory or recurrent multiple myeloma.
Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
[TBL] [Abstract][Full Text] [Related]
5. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib: targeting multiple tyrosine kinases in cancer.
Hasskarl J
Recent Results Cancer Res; 2014; 201():145-64. PubMed ID: 24756790
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
9. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
[TBL] [Abstract][Full Text] [Related]
10. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Gollob JA
Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
[TBL] [Abstract][Full Text] [Related]
12. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
Nishida N; Kitano M; Sakurai T; Kudo M
Dig Dis; 2015 Oct; 33(6):771-9. PubMed ID: 26488287
[TBL] [Abstract][Full Text] [Related]
15. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib for the treatment of multiple myeloma.
Gentile M; Martino M; Recchia AG; Vigna E; Morabito L; Morabito F
Expert Opin Investig Drugs; 2016 Jun; 25(6):743-9. PubMed ID: 26998658
[TBL] [Abstract][Full Text] [Related]
17. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
18. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Shen CT; Qiu ZL; Luo QY
Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
[TBL] [Abstract][Full Text] [Related]
20. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]